AI for Rare Diseases develops a specialized Rare Disease AI SLM — the world's most comprehensive AI-powered rare disease knowledge platform, freely available to patients, physicians, researchers, and organizations worldwide.
Rare Disease AI SLM
6 Specialized AI Agents
Global — Free Access
To develop a specialized Rare Disease AI SLM that serves as a continuously evolving digital rare disease expert — assisting clinicians, supporting patients, accelerating research, and enabling global access to rare disease expertise regardless of geographic location.
A future where no patient remains undiagnosed, no researcher lacks access to critical knowledge, and no promising treatment opportunity goes undiscovered — with the core Rare Disease AI agent available worldwide at no cost to patients, physicians, and researchers.
Unlike conventional medical AI trained on broad datasets, the RD-AI SLM combines outputs from leading AI systems — ChatGPT, Gemini, Claude, and specialized medical AI — through a proprietary consensus engine that generates higher-confidence clinical knowledge through evidence-based reconciliation.
Designed specifically for orphan diseases and genetic disorders — not a generic medical chatbot.
Peer-reviewed publications, NIH, Orphanet, NORD, genomic databases, EHRs, and patient registries.
HIPAA and GDPR compliant with privacy-preserving AI methods and continuous model auditing.
Core diagnostic and treatment AI freely available to patients, physicians, researchers, and developing nations.
A family of six specialized AI agents, each purpose-built to address a distinct challenge in the rare disease journey — from first diagnosis to breakthrough therapies.
Disease Identification & Differential Diagnosis
Precision Treatment & Care Guidance
Scientific Discovery & Knowledge Extraction
Pharmaceutical & Biotech Research Support
Education, Guidance & Disease Management
Global Trial Matching & Recruitment
The core Diagnostic & Treatment AI Agents are available worldwide at no cost to patients, physicians, researchers, academic institutions, rare disease advocacy organizations, and developing nations.
The RD-AI SLM platform delivers comprehensive AI-powered support across the full rare disease journey — from first symptoms to therapeutic innovation.
The Rare Disease AI SLM has the potential to transform outcomes at every stage of the patient journey and research pipeline.
Reduce diagnostic delays from years to months or weeks
Higher diagnostic accuracy through multi-source AI consensus
Rare disease expertise available regardless of geography or economic status
Faster scientific discovery and knowledge synthesis across disease areas
Fewer unnecessary tests and faster pathways to correct diagnosis
AI-accelerated drug discovery and clinical trial optimization
The success of this initiative depends on active participation from the global rare disease community. We believe that patients and caregivers should be partners — not merely beneficiaries — in the development of AI solutions.
Through collaborative governance and stakeholder engagement, we ensure the platform reflects the real-world needs and priorities of the communities it serves.
Become a PartnerOur goal is not to replace healthcare professionals but to augment their capabilities. The platform implements human-in-the-loop validation and physician oversight at every step.
Physician oversight mechanisms at every critical decision point — AI augments, never replaces.
HIPAA and GDPR compliant with privacy-preserving AI methods and continuous model auditing.
AI decisions are interpretable, auditable, and communicated clearly with evidence-based scoring.
All AI capabilities undergo rigorous validation in real clinical environments before deployment.
Proactive bias detection and mitigation to ensure equitable outcomes across all populations.
Patient safety and ethical responsibility are foundational — embedded at every system layer.
We seek strategic partnerships and foundational support from government agencies, philanthropic organizations, research institutions, healthcare systems, and private-sector stakeholders throughout the United States, Europe, and beyond.
This initiative is a global non-profit effort — our commitment is that core AI agents will be freely available worldwide.
By combining multi-LLM intelligence, biomedical knowledge, genomic analytics, and a mission-driven nonprofit model, we are building the world's most comprehensive rare disease intelligence platform.
Together, we can create a future where every rare disease patient receives an accurate diagnosis, personalized care, and access to the best science — anywhere in the world.